AI Article Synopsis
- - The text discusses a case of hemophagocytic intravascular large B-cell lymphoma (IVLBCL) that has affected the central nervous system (CNS) and highlights the challenges in improving prognosis despite the use of the R-CHOP chemotherapy regimen.
- - Research into gene and molecular profiling, particularly focusing on the BCR/TLR/IL-1R/NF-κB signaling pathway, is suggested as a potential avenue for developing new therapies for IVLBCL.
- - The case involves treating a patient with CNS-involved hemophagocytic IVLBCL using a Bruton tyrosine kinase inhibitor (BTKi), specifically zanubrutinib, which proved to be a feasible and effective
Article Abstract
This is a case of hemophagocytic intravascular large B-cell lymphoma (IVLBCL) with central nervous system (CNS) involvement. Although R-CHOP chemotherapy regimen has been shown significant improvement in survival rate. The prognosis and outcomes remain unsatisfactory, which is identified as outstanding challenges and need solutions. Gene and molecular profiling studies may provide new therapeutic strategies, especially the BCR/TLR/IL-1R/NF-κB signaling pathway in IVLBCL. Here, we treated the hemophagocytic IVLBCL CNS-involved patient with the Bruton tyrosine kinase inhibitor (BTKi) to block NF-κB pathway, and indicated that the second-generation BTKi zanubrutinib-based treatment was feasible and efficient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325336 | PMC |
| http://dx.doi.org/10.1177/20406207241270788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!